Kerala Ayurveda Approves Rs 137.1 Mln Preferential Issue

KOCHI — The Board of Directors of Kerala Ayurveda Limited has approved a preferential issue of equity shares worth up to Rs 137.1 million ($1.64 million / Rs 13.71 crore) at an issue price of Rs 190.37 per share, according to a statutory regulatory disclosure filed with stock exchanges on Friday. The proposed capital raise aims to fund working capital requirements, strengthen manufacturing operations, and accelerate brand distribution across domestic and overseas wellness markets.

The funding approval comes amid growing consumer adoption of traditional wellness therapies and standardized Ayurvedic formulations, prompting specialized healthcare manufacturers to expand manufacturing capacity and digital outreach.

Preferential Issue Structure and Valuation

The capital mobilization will occur via the issuance and allotment of fresh equity shares on a preferential basis, subject to shareholder approval and regulatory clearances under SEBI ICDR regulations:

• Aggregate Issue Size: Up to Rs 137.1 million (Rs 13.71 crore).

• Issue Price: Fixed at Rs 190.37 per equity share, determined in line with statutory pricing formulas under Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.

• Allotment Mechanism: Direct preferential allotment to identified non-promoter and strategic investors to enhance operating liquidity.

According to the exchange filing, the capital raised from the preferential allotment will support the company's long-term business strategy, including capacity optimization across manufacturing units, repayment of high-cost debt, and funding digital sales platforms.

Strategic Growth and Commercial Trajectory

Kerala Ayurveda Limited operates a traditional healthcare ecosystem encompassing proprietary formulation manufacturing, Ayurveda academies, wellness resorts, and outpatient clinics.

Headquartered in Aluva, Kochi, the company produces over 350 classic and proprietary Ayurvedic formulations, supported by herbal research facilities and clinical trial units. Under its modern distribution strategy, Kerala Ayurveda has been integrating its traditional formulations with over-the-counter (OTC) wellness platforms, targeting lifestyle management segments such as preventive immunity, digestive health, stress relief, and joint care.

The fresh equity infusion is intended to expand product availability across Tier-1 and Tier-2 domestic markets, while providing regulatory compliance capital for market authorisations across North America and Europe.

Market and Investor Implications

The preferential issue announcement carries measurable consequences for various market stakeholders:

• Existing Shareholders: The issue will result in equity dilution, but the influx of growth capital at Rs 190.37 per share helps establish an equity valuation floor.

• Balance Sheet Stability: Deploying the Rs 137.1 million toward operational working capital and deleveraging is expected to lower finance expenses and strengthen operating margins.

• Consumers and Patients: Expanded capital enables the firm to accelerate modernization of wellness centers and scale availability of clinically standardized Ayurvedic formulations.

Official Sources Section

Details regarding the equity pricing, issuance quantum, and corporate governance actions are drawn from:

• Regulatory filings submitted under Regulation 30 of SEBI (LODR) Regulations to BSE Limited.

• Corporate announcements and investor updates filed with the National Stock Exchange of India (NSE).

• Statutory compliance registries maintained by the Ministry of Corporate Affairs (MCA).

• Preferential issue pricing and disclosure guidelines formulated by the Securities and Exchange Board of India (SEBI).

Quote Section

According to official disclosures filed with stock bourses:

"The Board of Directors has considered and approved the raising of funds through the issuance of equity shares on a preferential basis for an aggregate amount not exceeding Rs 137.1 million, at a price of Rs 190.37 per share, in accordance with the provisions of SEBI ICDR Regulations and the Companies Act, 2013. The proceeds will be utilized to strengthen capital structure, finance business operations, and support strategic growth initiatives."

Why It Matters

Capital access remains essential for legacy Ayurvedic and herbal pharmaceutical manufacturers transitioning to modernized production and global distribution. Raising Rs 137.1 million at Rs 190.37 per share gives Kerala Ayurveda the financial headroom needed to scale production runs, satisfy growing domestic demand, and meet international testing standards, supporting growth without overleveraging its balance sheet.

Key Facts at a Glance

• Total Issue Value: Up to Rs 137.1 million (Rs 13.71 crore).

• Issue Price: Rs 190.37 per equity share.

• Mode of Issuance: Preferential allotment under SEBI ICDR Regulations.

• Capital Utilization: Working capital expansion, product distribution, and general corporate purposes.

• Governance Status: Approved by the Board of Directors; subject to standard shareholder confirmation.

Frequently Asked Questions

What is the issue price set for Kerala Ayurveda's preferential issue?

The issue price has been fixed at Rs 190.37 per equity share, calculated in accordance with SEBI pricing guidelines for preferential issues.

What is the total value of the preferential issue approved by Kerala Ayurveda?

The Board of Directors approved raising capital of up to Rs 137.1 million (Rs 13.71 crore).

How will the proceeds from the share sale be used?

The proceeds will be deployed to fund general working capital requirements, expand proprietary product manufacturing, strengthen distribution networks, and support strategic corporate initiatives.

Is the preferential issue subject to shareholder approval?

Yes. The preferential allotment requires statutory approval from shareholders via an extraordinary general meeting or postal ballot, alongside standard regulatory approvals.

Source: Official regulatory announcements published via BSE Limited, National Stock Exchange of India (NSE), and the Securities and Exchange Board of India (SEBI).